Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm	Recruiting	Phase 3	2022-06-01		NCT04807673

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	294
Harbin Medical University	42
Hebei Medical University Fourth Hospital	83
Jining First People's Hospital	26
Liaoning Cancer Hospital & Institute	53
Ruijin Hospital	454
Shandong Provincial Hospital	112
Shanghai Chest Hospital	116
Shanxi Province Cancer Hospital	43
Tianjin Medical University Cancer Institute and Hospital	287
Tianjin Medical University General Hospital	80
Weifang People's Hospital	30

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital	Tianjin	China	1